PFE — Pfizer Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual income statement for Pfizer, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2019 December 31st	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	41,172	41,651	81,288	100,330	58,496
Cost of Revenue
Gross Profit	33,129	33,246	50,602	66,233	40,707
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	28,841	34,117	57,802	64,093	59,425
Operating Profit	12,331	7,534	23,486	36,237	-929
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	11,485	7,036	24,311	34,729	1,058
Provision for Income Taxes
Net Income After Taxes	10,545	6,666	22,459	31,401	2,173
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	16,273	9,159	21,980	31,372	2,119
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	16,272	9,159	21,979	31,372	2,119
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.23	1.45	5.12	6.28	3.2
Dividends per Share